<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hu W</submitter><funding>the National Natural Science Foundation of China</funding><pagination>95</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11656970</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>H1-antihistamines are widely used to treat symptoms depending on histamine release in a variety of conditions. However, neurological adverse events have been reported in post-marketing surveillance studies and there are limited literatures comparing the neurological disorders associated with newer-generation H1-antihistamines from real-world datasets.&lt;h4>Aims&lt;/h4>We performed a comparative analysis of nervous system disorders and several newer-generation H1-antihistamines including: cetirizine, loratadine, levocetirizine, desloratadine and fexofenadine.&lt;h4>Methods&lt;/h4>Disproportionality analysis was used to identify the suspected drug neurological adverse events associated with H1-antihistamines of interest via the Food and Drug Administration Adverse Event Reporting Sys</pubmed_abstract><journal>BMC pharmacology &amp; toxicology</journal><pubmed_title>Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.</pubmed_title><pmcid>PMC11656970</pmcid><funding_grant_id>No. 82071686</funding_grant_id><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Zeng L</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Gan J</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Feng C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.</name><description>&lt;h4>Background&lt;/h4>H1-antihistamines are widely used to treat symptoms depending on histamine release in a variety of conditions. However, neurological adverse events have been reported in post-marketing surveillance studies and there are limited literatures comparing the neurological disorders associated with newer-generation H1-antihistamines from real-world datasets.&lt;h4>Aims&lt;/h4>We performed a comparative analysis of nervous system disorders and several newer-generation H1-antihistamines including: cetirizine, loratadine, levocetirizine, desloratadine and fexofenadine.&lt;h4>Methods&lt;/h4>Disproportionality analysis was used to identify the suspected drug neurological adverse events associated with H1-antihistamines of interest via the Food and Drug Administration Adverse Event Reporting Sys</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-03T23:13:18.463Z</modification><creation>2025-04-03T23:13:18.463Z</creation></dates><accession>S-EPMC11656970</accession><cross_references><pubmed>39696617</pubmed><doi>10.1186/s40360-024-00822-x</doi></cross_references></HashMap>